SOURCE: SpectraScience, Inc.

SpectraScience, Inc.

June 29, 2012 09:00 ET

SpectraScience Begins Shipments of WavSTAT4 Optical Biopsy System to PENTAX in Europe

SAN DIEGO, CA--(Marketwire - Jun 29, 2012) - SpectraScience, Inc. (OTCQB: SCIE) (PINKSHEETS: SCIE), a San Diego-based medical device company, has begun initial shipments of its WavSTAT4 Optical Biopsy System to PENTAX Europe GmbH under the exclusive, 5-year distribution agreement announced earlier this month. The agreement, which includes the WavSTAT4 mobile console and disposable optical biopsy forceps, covers Europe as well as Turkey, Saudi Arabia, and South Africa.

"This initial order for delivery of systems intended for customers in The Netherlands, France, Germany and the United Kingdom reflects PENTAX' strategy to quickly incorporate WavSTAT4 into their colorectal screening business," said Michael Oliver, SpectraScience's Chief Executive Officer. "Our engineering and manufacturing teams are in the process of ramping up training programs and production plans to make certain we provide everything PENTAX requires under the agreement."

PENTAX is a leading provider of minimally invasive surgical devices, including flexible endoscopes which are used with the WavSTAT4 System during screening for colorectal cancer. The WavSTAT4 Optical Biopsy System is designed to be used as an adjunct to existing endoscopic procedures, and can provide an in vivo diagnosis of possible cancerous tissue immediately during a typical colorectal screening. The results of the WavSTAT4 diagnosis are immediately displayed on the system console -- a red icon denoting cancerous tissue, and a green icon for normal tissue.

About SpectraScience, Inc.

SpectraScience is a San Diego-based medical device company that designs, develops, manufactures and markets light-based analysis systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically diagnose tissue and provide the physician with an immediate analysis. With approval for sale under the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use.

Contact Information

  • Contact:
    SpectraScience, Inc.
    Jim Dorst
    Chief Financial Officer
    (858) 405-9933

    Investor Relations
    Don Markley
    Email Contact
    (310) 691-7100